Candel Therapeutics (CADL) Set to Release Quarterly Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) is projected to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.3372) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.28). On average, analysts expect Candel Therapeutics to post ($1.29) EPS for the current fiscal year and ($1.27) EPS for the next fiscal year.

Candel Therapeutics Price Performance

CADL stock opened at $9.49 on Tuesday. The stock has a market capitalization of $726.17 million, a PE ratio of -6.73 and a beta of -0.27. The company’s 50-day moving average is $10.13 and its 200-day moving average is $8.35. The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09. Candel Therapeutics has a 1 year low of $4.35 and a 1 year high of $14.00.

Analyst Ratings Changes

CADL has been the topic of a number of research reports. Zacks Research downgraded Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Wall Street Zen lowered Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Stifel Nicolaus initiated coverage on Candel Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $22.00 price objective for the company. Bank of America upgraded Candel Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $12.00 to $18.00 in a report on Monday, September 21st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Candel Therapeutics in a research report on Friday, October 2nd. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.43.

Insider Buying and Selling

In other news, CTO Seshu Tyagarajan sold 7,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the completion of the sale, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at $922,380. This represents a 8.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 14.30% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics, Inc is a clinical-stage biopharmaceutical company developing biological immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach uses engineered viral therapies intended to promote immunogenic cell death and generate broader, potentially systemic antitumor immune responses.

Candel’s pipeline includes CAN-3110, an investigational oncolytic immunotherapy based on a genetically engineered herpes simplex virus type 1.